|
Research
Front Name
|
Percentage of corporate affiliations
|
Leading
corporation
|
|
ELECTROSPRAY-ATMOSPHERIC PRESSURE CHEMICAL IONIZATION
MASS SPECTROMETRY PLASMA MATRIX EFFECTS; QUANTITATIVE
LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY
|
36
|
Merck & Co., Inc.
|
|
VIRTUAL SCREENING USING PROTEIN-LIGAND DOCKING; FULLY
AUTOMATIC FLEXIBLE MOLECULAR DOCKING; SIMILARITY-BASED
VIRTUAL SCREENING USING 2D FINGERPRINTS
|
29
|
Schrodinger, LLC
|
|
EARLY DRUG DISCOVERY USING HIGH-RESOLUTION LIQUID
CHROMATOGRAPHY/QUADRUPOLE TIME-OF-FLIGHT MASS
SPECTROMETRY
|
29
|
Waters Corp.
|
|
HUMAN PROTEIN INTERACTIONS; GENE MENTION FINDING
EVALUATION; BIOCREATIVE TASKS; PROTEIN INTERACTION
INFORMATION
|
27
|
Mitre Corp.
|
|
DIPEPTIDYL PEPTIDASE-4 INHIBITOR VILDAGLIPTIN;
BETA-CELL FUNCTION; TYPE 2 DIABETES MELLITUS
INADEQUATELY CONTROLLED; TYPE 2 DIABETES FAILING
THIAZOLIDINEDIONE MONOTHERAPY
|
25
|
Merck & Co., Inc.
|
|
SUBOPTIMALLY CONTROLLED TYPE 2 DIABETES; TYPE 2
DIABETES PREVIOUSLY UNCONTROLLED; EXENATIDE EFFECTS;
MONOTHERAPY SIGNIFICANTLY IMPROVES GLYCEMIC CONTROL
|
25
|
Amylin Pharmaceuticals, Inc.
|
|
NONINFLAMMATORY SYNTHETIC SIRNA; POTENT GENE SILENCING
IN-VIVO; SMALL INTERFERING RNA INHIBITS TUMOR GROWTH;
CHEMICALLY MODIFIED SMALL INTERFERING RNAS
|
23
|
Alnylam Pharmaceuticals, Inc.
|
|
SMALL-MOLECULE MDM2 ANTAGONISTS; ABERRANT P53
SIGNALING; MDM2 ANTAGONISTS ACTIVATE P53; LETHAL P53
ACTIVITY IN-VIVO; GENOMIC ANALYSIS IDENTIFIES P53
STATUS
|
23
|
Hoffmann-La Roche Inc.
|
|
TUMOUR SUPPRESSOR CYLD; NF-KAPPA B SIGNALLING; A20
DOWNREGULATE NF-KAPPA B SIGNALLING; NF-KAPPA B PATHWAY;
I KAPPA B KINASE ACTIVATION
|
21
|
Genentech, Inc.
|
